MAP2K7 and differentiated thyroid carcinoma: The results offer new insight into overcoming chemoresistance in preclinical HNSCC models and contribute to the further use of MEK inhibitors in clinical research.344 The MEK inhibitor selumetinib has been approved in advanced differentiated thyroid carcinoma.345 However, some tumors develop MEKi resistance, but the mechanism remains unknown.